Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Hepatocellular carcinoma (HCC) is one of the commonest cancers worldwide and ranks the third on the incidence of cancer-related death. There are more than 500000 new cases diagnosed annually worldwide. The incidence and prevalence of HCC are on rising trend with the majority of the disease burden is in Asia where viral hepatitis B is endemic. Surgical resection, radiofrequency ablation (RFA) and liver transplantation (LT) represent the only chance of cure for HCC patients. Despite more aggressive surgical approach has been adopted in most Asian countries, yet curative intervention remains only amendable in 30% of patients. Most patients are diagnosed with intermediate or advanced stage diseases; the long-term cure rate is only 0-10%. Hence, every effort has been made in an attempt to convert inoperable HCC into operable disease (i.e. downstaging) in order to improve the chance of survival of these patients. The current study, to current knowledge, will be the first study in the field to deploy a novel treatment strategy to deploy both immunotherapy and stereotactic beamed radiotherapy to induce tumor shrinkage rendering it become operable cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak wątroby rozpoznany zgodnie z wytycznymi medycznymi.
- •Guz wątroby o wielkości od 5 do 25 cm, lub maksymalnie 3 guzy, lub zajęcie fragmentu żyły wrotnej.
- •Wiek od 18 do 80 lat.
- •Dobra ogólna kondycja pacjenta (wynik ECOG 0 lub 1).
✗ Disqualifies
- •Wcześniejsze leczenie inwazyjne z powodu innego nowotworu.
- •Wcześniejsza radioterapia w okolicy wątroby.
- •Obecność przerzutów poza wątrobą.
- •Zakrzepica głównej żyły wrotnej lub żyły głównej dolnej.
- •Obecność płynu w jamie brzusznej lub zaburzeń świadomości.
- •Bardzo duży guz (>15 cm) lub sumaryczna wielkość guzów (>25 cm) lub więcej niż 3 guzy.
- •Bezpośrednie naciekanie guza na żołądek, dwunastnicę, jelito cienkie lub grube, lub drogi żółciowe.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Last updated (source)
- September 28, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Queen Mary Hospital
Hong Kong, Hong Kong
Trial contact
Albert Chan
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/29/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.